Advertisement
GH vs NTRA
Which Stock Would AI Choose? Guardant Health (GH) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Both GH and NTRA operate in precision oncology with strong revenue growth in recent quarters, but NTRA shows more consistent earnings beats.
- GH trades at around $87.60 with a market cap of $11.6 billion, while NTRA is at $207.28 with $29.6 billion, reflecting differing scale and valuation.
- Year-to-date, GH has gained 14.24%, outperforming NTRA's 9.52%, though GH experienced a recent monthly decline of about 9%.
- Recent analyst coverage favors NTRA with new Outperform ratings ahead of Q1 earnings.
- Both firms report negative EPS (earnings per share), with GH at -3.32 and NTRA at -1.51 TTM (trailing twelve months), amid ongoing investments in growth.
- Market sentiment highlights NTRA's expansion in oncology and transplant testing as a key differentiator.
Introduction
Guardant Health (GH) and Natera (NTRA) are leading players in precision oncology, specializing in cell-free DNA (cfDNA) testing for cancer detection and monitoring. This stock comparison analyzes their business models, recent performance, and market positioning amid evolving biotech trends. Investors focused on genomics and diagnostics, particularly those tracking liquid biopsy innovations, will find value in understanding their relative strengths. With both companies posting robust revenue growth in recent quarters but facing profitability challenges, the analysis highlights momentum shifts and growth drivers in the current market environment.
GH Overview and Recent Performance
Guardant Health (GH) is a precision oncology company offering liquid biopsy tests like Guardant360 and Shield for cancer therapy selection and multi-cancer early detection. In recent market activity, shares have traded around $87.60, with a market cap of approximately $11.6 billion and a 52-week range of $36.36 to $120.74. Year-to-date gains stand at 14.24%, though recent weeks saw a roughly 9% monthly pullback amid broader sector volatility. Q4 2025 results showed 39% revenue growth to support oncology and screening segments, despite a wider-than-expected loss. Sentiment has been influenced by reimbursement expansions, such as TRICARE coverage, but valuation concerns persist with negative EPS of -3.32 TTM and ongoing cash burn.
NTRA Overview and Recent Performance
Natera (NTRA) provides genetic testing solutions including Signatera for molecular residual disease in oncology, Panorama for prenatal screening, and Prospera for transplant surveillance. Shares recently closed at $207.28, boasting a $29.6 billion market cap and a 52-week range of $131.81 to $256.36. YTD performance is 9.52%, with stability in recent trading despite market fluctuations. Q4 2025 delivered 39.8% product revenue growth and a positive EPS surprise, alongside a 66.9% gross margin. Key sentiment drivers include Prospera data presentations at recent conferences and upcoming Q1 earnings on May 7, 2026, bolstered by fresh Outperform ratings from analysts like William Blair. EPS TTM is -1.51, reflecting investment in expansion.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 available bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ machine learning for real-time signals with built-in risk controls like 3% take-profit and 2% stop-loss corridors, suiting strategies from 5-minute scalps to swing trades lasting up to 49 days. Standout stats include annualized returns of 23.53% to 163.10%, win rates from 51.30% to 88.33%, profit factors up to 11.70, and profit-to-drawdown ratios reaching 17.02, targeting hot sectors like AI semiconductors and space amid current volatility. Explore these adaptive tools to align with dynamic market conditions.
Head-to-Head Comparison
Both GH and NTRA leverage cfDNA for oncology, but GH emphasizes comprehensive cancer screening via Shield, while NTRA diversifies into prenatal and transplant with Signatera and Prospera. Growth drivers include similar 39% recent revenue surges, yet NTRA's larger scale yields positive free cash flow versus GH's burn. Recent momentum favors NTRA with earnings beats and analyst upgrades, contrasting GH's post-earnings volatility. Risks involve competition in liquid biopsy, regulatory hurdles, and persistent losses (profit margins -42% for GH vs. -9% for NTRA). Sector exposure is tightly aligned in biotech diagnostics, but NTRA benefits from broader applications enhancing resilience.
Tickeron AI Verdict
Tickeron’s AI currently leans toward NTRA due to superior earnings consistency, positive analyst momentum, diversified revenue streams, and upcoming catalysts like Q1 results. While GH offers YTD outperformance and reimbursement tailwinds, NTRA's relative stability and growth trajectory position it more favorably in prevailing trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a Buy and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 0 green FA rating(s).
- GH’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 6 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- GH’s TA Score: 6 bullish, 4 bearish.
- NTRA’s TA Score: 4 bullish, 5 bearish.
Price Growth
GH (@Medical Specialties) experienced а -1.09% price change this week, while NTRA (@Medical Specialties) price change was -4.00% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +10.09%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was -4.21%.
Reported Earning Dates
GH is expected to report earnings on Jul 30, 2026.
NTRA is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (+10.09% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| GH | NTRA | GH / NTRA | |
| Capitalization | 13B | 28.1B | 46% |
| EBITDA | -390.98M | -227.7M | 172% |
| Gain YTD | -3.867 | -14.427 | 27% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 1.08B | 2.5B | 43% |
| Total Cash | 1.1B | 1.09B | 101% |
| Total Debt | 1.71B | 240M | 710% |
GH | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 53 | |
SMR RATING 1..100 | 100 | 94 | |
PRICE GROWTH RATING 1..100 | 42 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (56) in the Biotechnology industry is in the same range as GH (74) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
NTRA's Profit vs Risk Rating (53) in the Biotechnology industry is somewhat better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew somewhat faster than GH’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
GH's Price Growth Rating (42) in the Medical Or Nursing Services industry is in the same range as NTRA (60) in the Biotechnology industry. This means that GH’s stock grew similarly to NTRA’s over the last 12 months.
GH's P/E Growth Rating (100) in the Medical Or Nursing Services industry is in the same range as NTRA (100) in the Biotechnology industry. This means that GH’s stock grew similarly to NTRA’s over the last 12 months.
| GH | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | N/A |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Advances ODDS (%) | 8 days ago 79% | 8 days ago 80% |
| Declines ODDS (%) | 22 days ago 85% | 21 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 80% | 2 days ago 82% |
Advertisement
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.